Somanta

Somanta Pharmaceuticals was a clinical-stage biotechnology company focused on the development of novel oncology therapeutics. The company's research centered on the tumor microenvironment and the inhibition of angiogenesis to prevent cancer growth and metastasis. Its lead product candidate was a recombinant human angiostatin, a protein designed to block the blood supply to tumors. Additionally, Somanta developed Alchemix, a small molecule therapeutic intended to target multiple pathways in cancer cells. In 2007, the company was acquired by Adventrx Pharmaceuticals in an all-stock transaction to strengthen Adventrx's oncology pipeline. The company was headquartered in San Diego, California, and was previously traded on the OTC Bulletin Board.